60 completed, 9 active not recruiting, 6 terminated, 5 withdrawn. 38 Phase 2, 20 Phase 1, 9 Phase 3, 1 Not applicable, 1 Phase 4.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 38 | Completed 24, Active not recruiting 7, Terminated 3, Unknown 2, Withdrawn 2 |
| Phase 1 | 20 | Completed 12, Active not recruiting 3, Terminated 2, Withdrawn 2, Unknown 1 |
| Phase 3 | 9 | Completed 4, Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow radium Ra 223 dichloride: new trials by email Literature Review of radium Ra 223 dichloride trials Research Report on radium Ra 223 dichloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Active not recruiting | University of California, San Francisco | 2 | 2024-08-30 | 2026-01-14 |
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
Darolutamide, Radium-223 - Metastatic Prostate Cancer | Phase 3 | Withdrawn | GenesisCare USA | | 2023-09-01 | 2023-09-14 |
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Radium-223 dichloride (Xofigo, BAY88-8223) - Metastatic Castration-resistant Prostate Cancer, Bone Metastases | | Terminated | Bayer | 8 | 2022-09-15 | 2023-09-22 |
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Radium dichloride, PET Scan - Prostate Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2021-11-12 | 2026-04-28 |
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
Radium 223 dichloride (Xofigo, BAY88-8223) - Bone Metastatic Castration-resistant Prostate Cancer | | Completed | Bayer | 1067 | 2021-05-15 | 2024-03-08 |
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | | Recruiting | University of Washington | 48 | 2021-04-16 | 2026-10-22 |
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
Radium-223-dichloride (Xofigo, BAY88-8223) - Prostate Cancer | | Completed | Bayer | 103 | 2021-04-08 | 2023-10-26 |
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Radium-223 dichloride (Xofigo, BAY88-8223) - Bone Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | Bayer | 46 | 2020-11-16 | 2025-09-19 |
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Radium-223 dichloride (Xofigo, BAY88-8223), ARPI therapy - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 4 | Active not recruiting | Bayer | 654 | 2020-11-09 | 2026-07-06 |
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
Nivolumab, Radium-223 - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | University of Utah | 39 | 2020-09-16 | 2026-06-01 |
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2020-08-04 | 2026-09-18 |
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Radium-223 dichloride (Xofigo, BAY88-8223) - Metastatic Castration Resistant Prostate Cancer (mCRPC) | | Completed | Bayer | 1180 | 2020-08-03 | 2022-03-31 |
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
Radium-223 dichloride (Xofigo, BAY88-8223) - Castration-resistant Prostate Cancer | | Completed | Bayer | 194 | 2020-07-07 | 2024-07-17 |
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Terminated | MANA RBM | 23 | 2020-06-30 | 2022-10-07 |
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab - Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Bayer | 8 | 2020-03-06 | 2024-10-10 |
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
Radium-223 dichloride (Xofigo, BAY88-8223) - Prostate Cancer | | Completed | Bayer | 4301 | 2020-02-24 | 2022-06-23 |
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
Radium-223 dichloride (Xofigo, BAY88-8223), Other standard care - Metastatic Castration-Resistant Prostate Cancer | | Completed | Bayer | 1434 | 2020-02-15 | 2024-01-16 |
Showing 20 of 88. Sign in to see all of them.
Conditions studied
Prostatic Neoplasms (44) · Prostatic Neoplasms, Castration-Resistant (6) · Neoplasm Metastasis (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Multiple Myeloma (2) · Neoplasms (2) · Bone Diseases (1) · Bone Neoplasms (1) · Clear-cell metastatic renal cell carcinoma (1) · Fatigue (1) · Fractures, Bone (1) · Lung Neoplasms (1) · Lymphatic Metastasis (1)
Sponsors
Bayer (46) · National Cancer Institute (NCI) (4) · University of Utah (3) · Carolina Research Professionals, LLC (2) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Ajjai Alva, MD (1) · Amsterdam UMC, location VUmc (1) · Angela Taber MD (1) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · AstraZeneca (1) · Canadian Urology Research Consortium (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · City of Hope Medical Center (1)
Countries
United States (50) · Spain (15) · United Kingdom (15) · Germany (14) · France (13) · Israel (13) · Sweden (12) · Belgium (11) · Canada (11) · Italy (11) · Netherlands (11) · Norway (9) · South Korea (8) · Taiwan (8) · Finland (7)
Top investigators
Neal D Shore, MD (2) · Rana R McKay (2) · Ajjai Alva, M.D. (1) · Andre Bergman, MD, PhD (1) · Ashkan Mortezavi, MD, PhD (1) · Atish Choudhury, MD (1) · Bobby Liaw, MD (1) · Brandon Imber, MD (1) · Christopher Parker, MD (1) · David I Quinn, MD (1) · David Olmos, MD (1) · Elena Castro, MD (1)
Results publications
PMID 22214491, PMID 22341993, PMID 22513884, PMID 22546715, PMID 23000088, PMID 23653243, PMID 23863050, PMID 23977665, PMID 24052017, PMID 24610703, PMID 24775727, PMID 24836273, PMID 24857093, PMID 25439694, PMID 25832684, PMID 25840395, PMID 26182965, PMID 26854432, PMID 27272279, PMID 27473888, PMID 27930924, PMID 28478485, PMID 28770408, PMID 30612558, PMID 30738780, PMID 31082669, PMID 31311763, PMID 31442327, PMID 31823152, PMID 31849202, PMID 31937614, PMID 31959342, PMID 32404868, PMID 32586393, PMID 33451978, PMID 33575828, PMID 33604999, PMID 33619600, PMID 33744812, PMID 34108181, PMID 34168015, PMID 34636627, PMID 34645727, PMID 35027313, PMID 35190653, PMID 35317973, PMID 35804188, PMID 35981452, PMID 37385670, PMID 37838555
NIH funding
2014 (3), 2015 (3), 2016 (2), 2019 (2), 2023 (2), UM1CA186689 (2), 2004 (1), 2005 (1), 2009 (1), 2018 (1), P30CA014089 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186704 (1), UM1CA186716 (1)